RxDoctor Payments Data

Alicia Elliott

Psychiatric/Mental Health · Fort Wayne, INNPI 1699071100

Payments from drug & device makers

$4,918in general payments, 2019–2025

Across 96 payments — averaging $51.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$1K
  • Axsome Therapeutics, Inc.$958
  • Sunovion Pharmaceuticals Inc.$599
  • Neurocrine Biosciences, Inc.$526
  • E.r. Squibb & Sons, L.L.C.$425
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$325
  • plus $1K from 9 others

What the payments were for

  • Food & beverage$4,86599%
  • Education$521%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,918 in reported general payments places this provider in the 90th percentile of 729 psychiatric/mental health providers in Indiana.

See all psychiatric/mental health providers in Indiana

Medicare billing

Part B allowed, 2024
$8,268
Medicare patients
18
Services billed
82

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VraylarCariprazine Hcl12$17,080
AdderallDextroamphetamine/Amphetamine12$7,872
BelsomraSuvorexant14$6,089
Atomoxetine Hcl12$1,688
Quetiapine Fumarate56$730
Duloxetine Hcl31$683
Desvenlafaxine Succinate ErDesvenlafaxine Succinate22$628
Mirtazapine32$534
Hydroxyzine Hcl49$502
Nortriptyline Hcl47$406
Bupropion XlBupropion Hcl17$386
Aripiprazole17$350
Olanzapine12$279
Divalproex Sodium13$214
Bupropion Hcl13$201

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieVraylar$273$17,08012 claims
Takeda Pharmaceuticals U.S.A., Inc.Adderall$78$7,87212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 729 psychiatric/mental health providers in Indiana.

Other psychiatric/mental health in Fort Wayne

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →